The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
Consensus Recommendations for Use of p16/Ki67 Dual Staining Cytology in the Management of Individuals Testing Positive for HPV
Strategic Excellence: Mastering the Expanding ATTR-CM Therapeutic Landscape in Pharmacy Practice
Accurate Staging and Determining Resectability in NSCLC
Consolidation Immunotherapy After Concurrent CRT: What Do Real-World Data Show?
Consolidative Immunotherapy Following sCRT vs RT Only in Stage III NSCLC
Chemoradiotherapy Toxicities: How Do They Impact Starting Immunotherapy?
Consolidative Immunotherapy in Unresectable Stage III NSCLC With Oncogenic Drivers
Immunotherapy Approaches in Unresectable Stage III NSCLC: What’s on the Horizon?
Differentiating and Managing Pneumonitis in Unresectable Stage III NSCLC: Case Discussion
Resolving Practice Barriers to Consolidative Immunotherapy in Stage III NSCLC
Optimizing Consolidative Immunotherapy in Unresectable Stage III NSCLC: Case Discussion
Initial BTK Inhibitor-Based Treatment Selection in a Treatment-Naive, Symptomatic, Unfit Older Patient With Comorbidities and High-Risk Cytogenetics
Selection of BTK Inhibitor Following Frontline Chemoimmunotherapy in Older Patients With Comorbidities
Safety and Tolerability of Changing Covalent BTK Inhibitor Treatment in a Patient Intolerant to Ibrutinib or Acalabrutinib
ATTR-CM Management: Pearls From Recent Clinical Trials and Tailoring Therapy
Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
Are Two Pathways Better Than One? Experts Discuss the Role of Ang-2/VEGF-A Inhibition in Retinal Vascular Disease
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
The Role of Immunotherapy in the Treatment of Recurrent or Metastatic HNSCC: The Evidence
Current and Emerging Biomarkers of Response to Immunotherapeutic Regimens
Create your
podcast in
minutes
It is Free
RenaissanceOnlineRadio.com
Men in Lead Aprons
Denver Underground
Exercise: Learn To Love (Or At Least Like) It
NASACast Video